ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
12/11/2025
Back to search
Official data from USPTO
TETRAVARINEX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
45
Latest update
12/13/2025
Trademark type
Word
Nice classes
5
Filing date
05/30/2013
Registration date
08/12/2014
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/26/2021
Last transaction
12/13/2025
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
98
Owner location
GB
Examiner
REEVES,APRIL ELIZABETH
Law office
L20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Jazz Pharmaceuticals Research UK Limited
GW Research Limited
GW Pharma Limited
GW Pharma Limited
Representatives
Anessa Owen Kramer Honigman Miller Schwartz and Cohn LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and veterinary pharmaceutical preparationsherbsherbal extractsformulas containing herbal extractsmedicinal oils and pure extracts of medicinal plants and herbsfor use in the treatment of painmultiple sclerosisneuropathic painspinal cord injurybladder disfunctionperipheral neuropathycancer painperi-operative painrheumatoid arthritisinflammatory bowel diseaseneurogenic symptomspsychotic disordersdiseases of the central nervous systemstroke and head injurymotion sickness and chemically induced sicknessspasticityoncologycancer symptomspsychiatric illnessesneurodegenerative diseasesmetabolic disordersobesityobesity associated with type II diabetesbulimiaschizophreniaepilepsydravet syndromeneonatal hypoxiaseizuresalzheimersbone disordersdrugalcohol and nicotine abuseinflammatory disordersprotection of pancreatic islet cells in the treatment of diabetic or pre-diabetic patientsprotection of beta cells in the treatment of diabetic or pre-diabetic patientsmaintenance of insulin levelsimproved control of blood glucose levelstreatment of type I diabetestreatment of type II diabetes; pharmaceutical and veterinary pharmaceutical preparations for the treatment of painmultiple sclerosisneuropathic painspinal cord injurybladder disfunctionperipheral neuropathycancer painperi-operative painrheumatoid arthritisinflammatory bowel diseaseneurogenic symptomspsychotic disordersdiseases of the central nervous systemstroke and head injurymotion sickness and chemically induced sicknessspasticityoncologycancer symptomspsychiatric illnessesneurodegenerative diseasesmetabolic disordersobesityobesity associated with type II diabetesbulimiaschizophreniaepilepsydravet syndromeneonatal hypoxiaseizuresalzheimersbone disordersdrugalcohol and nicotine abuseinflammatory disordersprotection of pancreatic islet cells in the treatment of diabetic or pre-diabetic patientsprotection of beta cells in the treatment of diabetic or pre-diabetic patientsmaintenance of insulin levelsimproved control of blood glucose levelstreatment of type I diabetestreatment of type II diabetes; herbs for medicinal purposes; herb teas for medicinal purposes; plant extracts for pharmaceutical purposes
Publications
History of USPTO decisions and trademark events.
45 publications found
INNT
TOTAL INVALIDATION PROCESSED BY THE IB
01/30/2023
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
12/28/2022
INPC
INVALIDATION PROCESSED
12/28/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/24/2021
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
10/26/2021
C71T
CANCELLED SECTION 71
02/26/2021
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
10/09/2019
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
08/12/2019
CHLD
CHANGE OF OWNER RECEIVED FROM IB
09/13/2018
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/21/2017
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/29/2017
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/29/2017
RNWL
INTERNATIONAL REGISTRATION RENEWED
12/15/2016
INNT
TOTAL INVALIDATION PROCESSED BY THE IB
09/24/2015
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
06/19/2015
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/30/2015
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/06/2015
FIMP
FINAL DISPOSITION PROCESSED
01/06/2015
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/12/2014
R.PR
REGISTERED-PRINCIPAL REGISTER
08/12/2014
GPNX
NOTIFICATION PROCESSED BY IB
06/13/2014
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/27/2014
PUBO
PUBLISHED FOR OPPOSITION
05/27/2014
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/07/2014
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
05/07/2014
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/07/2014
PBPR
WITHDRAWN FROM PUB - ESU SUPERVISOR REQUEST
04/22/2014
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
04/22/2014
ALIE
ASSIGNED TO LIE
04/18/2014
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/28/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/24/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/24/2014
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/24/2014
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/02/2014
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/02/2014
RFNT
REFUSAL PROCESSED BY IB
10/20/2013
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/25/2013
RFRR
REFUSAL PROCESSED BY MPU
09/25/2013
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/24/2013
CNRT
NON-FINAL ACTION WRITTEN
09/23/2013
DOCK
ASSIGNED TO EXAMINER
09/15/2013
MAFR
APPLICATION FILING RECEIPT MAILED
07/26/2013
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/22/2013
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
07/18/2013
Continuous trademark protection
Get notified about every new filing that threatens TETRAVARINEX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.